<DOC>
	<DOCNO>NCT02742480</DOCNO>
	<brief_summary>SEDMAN study prospective multicenter investigator initiate study ( IIS ) . The main idea look Genome Wide Association ( arrays determine 1 million polymorphism ) genetic risk factor associate response dabigatran . To conduct study , goal recruit 300 patient ischemic stroke cardioembolic etiology treat dabigatran 200 treat Acenocoumarol determine genetic risk factor associate occurrence bleed vascular event year follow-up .</brief_summary>
	<brief_title>Dabigatran Study Early Phase Stroke . New Neuroimaging Markers Biomarkers Study ( SEDMAN STUDY )</brief_title>
	<detailed_description>Data analyze GWAS analysis . The result analyze experienced genotypic bioinformatics : Plink , Haploview , STATA , IMPUTE2 , SNPtest , GTOOL , Galaxy management . In addition , investigator support Spanish Consortium Genetics Stroke ( Genestroke ) . The PLINK software main program analysis GWAS . Using software clean raw result genotyping platform determine presence risk allele associate resistance study drug . Haploview software use data management graphic significance analysis . STATA statistical software data management useful creation Q_Q plot graph assist interpretation genotypic result . GTOOL , SNPtest IMPUTE2 software data imputation analysis impute data information available 1000 Genomes Project .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>Patients sex ≥ 18 year age Patients stroke TIA last 14 day diagnosis nonvalvular atrial fibrillation initiate treatment dabigatran classical ACOs ( acenocoumarol ) prevent stroke nonCNS systemic embolism . Patients mild/moderate stroke ( i.e . stroke less 2/3 vascular territory initial ASPECTS first CT/MRI &gt; 6 NIHSS &lt; 25 ) . Patients overall condition allow 12 month ' followup . Patients indication oral anticoagulant primary prevention indication cardioembolic etiology . Patients contraindication use anticoagulant . Patients wish participate study sign informed consent . Patients noncontrolled hypertension hypertensive crisis also exclude . Patients life expectancy le one year . Patients psychological social factor allow correct followup . Patients severe/disabling stroke ( i.e . 2/3 vascular territory , NIHSS≥25 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stroke</keyword>
	<keyword>oral anticoagulant</keyword>
	<keyword>cardioembolic</keyword>
</DOC>